Effectiveness and Safety of High Dose Primaquine and Tafenoquine in Plasmodium vivax Patients (EFFORT) - A Multi-Centre, Open Label, Superiority Randomised Controlled Trial
Tamiru Shibiru Degaga(Charles Darwin University), Muthoni Mwaura(Charles Darwin University), Anjana Rai, Amna Ibrahim(Beni-Suef University), Taj Muhammad(Aga Khan University), Sarah A. Cassidy-Seyoum(Charles Darwin University), Tariq Mehmood(Aga Khan University Nairobi), Dagimawie Tadesse Abate(Arba Minch University), Meas Sokha(Mahidol University), Mom Ean(Mahidol University), Sophie Weston(University of Oxford), Angela Rumaseb(Charles Darwin University), Rintis Noviyanti(Eijkman Institute for Molecular Biology), Tedla Teferi Tego(Arba Minch University), Benedikt Ley(Charles Darwin University), Arjen M. Dondorp(Angkor Hospital for Children), Ayodhia Pitaloka Pasaribu(Universitas Darma Agung), Rodas Temesgen(Arba Minch University), Angela Devine(Charles Darwin University), Agatha Mia Puspitasari, Yulita Yulita(Indonesian Coral Reef Foundation), Bipin Adhikari(Mahidol University), Nasreen A. Syed(Aga Khan University), Grant Lee(Charles Darwin University), Hellen Mnjala(Charles Darwin University), Rupam Tripura(Mahidol University), Robert J. Commons(Charles Darwin University), Megha Rajasekhar(The University of Melbourne), James J. Callery(Mahidol Oxford Tropical Medicine Research Unit), Umair Ali(Islamia University of Bahawalpur), Bushra Qurashi(Aga Khan University), Pinkan Kariodimedjo, Peixuan Li(The University of Melbourne), Ery Setiawan(Charles Darwin University), Najia Karim Ghanchi(Aga Khan University), F. Jabbar(Aga Khan University), Samuel Alemu Bamboro(Arba Minch University), Nurfadhilah Hasibuan(Indonesian Coral Reef Foundation), Widaya Safitri(Indonesian Coral Reef Foundation), Dedi Sahat Parningotan Siagian(Universitas Baturaja), Deni Syahputra(Universitas Baturaja), Khuda Dost(Aga Khan University), Edwin Sutanto(Charles Darwin University), Eyerusalem Beyene Erjabo(Arba Minch University)
Cited by 4
Related Papers
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline <i>BRCA</i>-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
|Clinical Cancer Research|2015|532
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
|Clinical Cancer Research|2015|377
FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
|Clinical Cancer Research|2014|350
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
|Journal of Clinical Oncology|2019|348